David A. Broecker was the CEO of Alkermes Inc., a biopharmaceutical company, from 2007 to 2009. He stepped up from being the President and COO, showing a clear career progression within the company. Before joining Alkermes, he worked at Eli...

David A. Broecker was the CEO of Alkermes Inc., a biopharmaceutical company, from 2007 to 2009. He stepped up from being the President and COO, showing a clear career progression within the company. Before joining Alkermes, he worked at Eli Lilly for nearly 16 years, managing one of their largest facilities in Ireland and holding various key positions in Europe and the U.S. Broecker played a crucial role in the commercial success of VIVITROL, a medication for addiction. Interestingly, he had a significant salary of over $1.6 million in 2009, which included a notable severance package after he left. His unique combination of operational experience and leadership in the pharmaceutical industry highlights his influence on Alkermes during a period of growth and change, positioning the company for future endeavors.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Alkermes CEOs

A

David A. Broecker

Ex-CEO of Alkermes

Education

Not specified

Sector of Economy

Healthcare

Born

January 1, 1962 - 63 years ago

CEO of Alkermes for

2 years 3 months (May 2007 - Sep 2009)

Previous Experience

Not specified

Rivals

Competitors/colleagues of David A. Broecker

M

August J. Troendle

Founder and CEO of Medpace Holdings, Inc.

2023 Compensation

Stock

$0.00

Salary

$825.00K

Bonus

$814.42K

Other

$17.33K

Total Holdings

$1.76B

O

Nchacha E. Etta

CEO of Omnicell

2023 Compensation

Stock

$1.50M

Salary

$259.42K

Bonus

$50.00K

Other

$9.00K

Total Holdings

$4.35M

Holdings

See how much did David A. Broecker make over time.

During his tenure, David A. Broecker held substantial stock options in Alkermes, particularly as part of his compensation package. In 2009, his total compensation included $393,750 in options that vested upon his departure, which forced him to cash out on...

During his tenure, David A. Broecker held substantial stock options in Alkermes, particularly as part of his compensation package. In 2009, his total compensation included $393,750 in options that vested upon his departure, which forced him to cash out on those due to his high-profile resignation. At one point, his vested stock grew to include major equity awards, reflecting his commitment to the company. This financial stake mirrored his role in promoting Alkermes while he was at the helm. However, he faced challenges that would lead to his early exit, notably when he could no longer align with the company's strategic direction post-2008. His holdings shifted dramatically as he transitioned out, indicating a significant part of his wealth was tied to the performance and management of Alkermes. Overall, Broecker's financial journey with the company serves as an insight into the risks and rewards of leadership in the ever-volatile pharmaceutical sector.

Loading...

Insider Trading

See recent insider trades of David A. Broecker.

No insider trades found for this CEO.

Compensation History

See how much did David A. Broecker make over time.

David A. Broecker's compensation as CEO of Alkermes varied over his tenure. In 2009, he earned a total of $1,661,865, which included a base salary of $509,615 and an impressive severance payment of $1,151,250 following his resignation. This severance highlighted the challenges he faced at Alkermes, reflecting both the financial commitment and risk encountered by leaders in the industry. In 2008, his compensation peaked at $1,996,572, with bonuses reflecting his contributions to corporate performance. Notably, he did not receive bonuses in some years, including 2009, indicating a shift in the company's performance. His compensation was designed to attract and retain experienced executives, but it also shows the pressure of aligning with company success. Overall, Broecker's financial package exemplified the high stakes of pharmaceutical leadership during his time.

Year

2009

Total Compensation

$1.66M

Salary

$509.62K

Board Justification

The compensation philosophy is designed to attract, retain, and motivate experienced executives, aligning compensation with company performance and peer benchmarking.

Bonus

$0.00

Board Justification

No bonus was awarded for the fiscal year 2009.

Other

$1.15M

Board Justification

Severance payment of $1,151,250 as part of the separation agreement.

Restricted Stock

$0.00(0 Restricted Stock Units (RSUs))

Board Justification

No stock was vested in 2009 as the stock awards were cancelled upon resignation.

Performance Metrics

Performance metrics included achieving corporate objectives related to product commercialization and financial performance.

Other Alkermes CEOs

Here are other CEOs of Alkermes

Richard F. Pops

CEO of Alkermes

September 2009 - Present